EASD 2026: Semaglutide dose escalation shows lower CV risk vs tirzepatide in diabetes

ConferencepositiveSemaglutideTirzepatidePositive

AI Analysis

Summary

Semaglutide dose escalation demonstrated lower cardiovascular risk compared to tirzepatide in adults with type 2 diabetes, data presented at EASD 2026 conference.

Clinical Trial Data

Outcome Details

Semaglutide dose escalation associated with lower cardiovascular risk compared to switching to tirzepatide

Importance:6/10

Sentiment:

0.60

EASD 2026diabetescardiovascular safetycomparative efficacyGLP-1 agonistGIP/GLP-1 receptor agonist

Related Companies

$NVO $LLY

Read the original article

Published by Clinical Trials Arena on September 29, 2026 7:40 PM

Read Original